Integra Therapeutics
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2024-09-01attributed |
| Founded | unknown |
| Headquarters | Barcelona, Spain |
| Industry | bio |
| Stage | unknown |
| Website | integra-tx.com |
Integra Therapeutics builds the FiCAT gene-writing platform, which combines CRISPR precision with engineered piggybac transposase for high-efficiency DNA transfer. It serves patients with genetic, oncological, and autoimmune diseases via partnered therapeutic programs. Recent results show inserting four therapeutic genes and removing one unwanted gene in a single intervention.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-09-01 | grant | $2.7M | undisclosed |
Detected tech stack
PHP 8.3.31, LiteSpeed Cache, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Site Kit 1.179.0, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.9, DoubleClick Floodlight, LiteSpeed, Python
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | integra-tx.com, read 2026-05-05 |
| Description | self-reported | integra-tx.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.